IDV vehicle
36E79724D0002
NEW AWARD FOR RANIBIZUMAB (BYOOVIZ) VIALS WITH BIOGEN U.S. CORPORATION. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $11.4M |
| Start date | Dec 23, 2023 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Nov 25, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Nov 25, 2025 | P00008 | $0 | BILATERAL MODIFICATION IS ISSUED TO NOTIFY BIOGEN U.S. CORPORATION, THAT THE GOVERNMENT WILL NOT EXERCISE THE 2ND OPTION YEAR FOR RANIBIZUMAB (BYOOVIZ) VIALS. THE CONTRACT WILL EXPIRE ON 12/22/2025 AT THE END OF THE 1ST OPTION YEAR. |
| Jan 31, 2025 | P00007 | $0 | INCORPORATE BIOGEN'S 2025 SUBK PLAN INTO CONTRACT. PLAN EFFECTIVE 1/1/2025 - 12/31/2025. |
| Nov 26, 2024 | P00006 | $0 | INCORPORATION OF THE 2025 FEDERAL CEILING PRICES FOR BIOGEN CONTRACT NUMBER 36E79724D0002. NC PRICE IS UNCHANGED. |
| Nov 25, 2024 | P00005 | $0 | EXERCISE THE FIRST OPTION YEAR FOR RANIBIZUMAB (BYOOVIZ) VIALS CONTRACT 36E79724D0002 WITH BIOGEN U.S. CORPORATION WITH NO PRICE CHANGES. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.